Table 1.
Baseline characteristics of the discovery and validation cohorts
| Characteristic | Discovery cohort (n = 9199) | Validation cohort (n = 4599) | |
|---|---|---|---|
| Age, yr | Mean (SD) | 52 (13) | 52 (13) |
| Range | 19, 85 | 21, 82 | |
| Women | 4532 (49.3) | 2289 (49.8) | |
| Self-reported Black race | 1748 (19.0) | 882 (19.2) | |
| Weight, kg | Mean (SD) | 82 (18) | 82 (18) |
| Range | 40, 180 | 41, 180 | |
| Height, cm | Mean (SD) | 171 (10) | 171 (10) |
| Range | 140, 200 | 140, 200 | |
| Estimated glomerular filtration rate | |||
| 60 ml/min/1.73 m2 | 6187 (67.7) | 3094 (67.7) | |
| 30–59 ml/min/1.73 m2 | 2160 (23.6) | 1079 (23.6) | |
| <30 ml/min/1.73 m2 | 796 (8.7) | 398 (8.7) | |
| Serum creatinine, mg/dla,c | Mean (SD) | 1.3 (0.6) | 1.3 (0.6) |
| Urine creatinine excretion (mg/d)b | Mean (SD) | 1338 (466) | 1345 (460) |
| Range | 43, 5175 | 45, 5125 | |
| Urine albumin excretion | |||
| ≥30 mg/d | 6308 (73.0) | 3119 (72.5) | |
| <30 mg/d | 2337 (27.0) | 1186 (27.5) | |
| Study cohort | |||
| CRIC | 2382 (25.9) | 1169 (25.4) | |
| MDRD | 528 (5.7) | 284 (6.2) | |
| JHS | 669 (7.3) | 341 (7.4) | |
| PREVEND | 5620 (61.1) | 2805 (61.0) | |
CRIC, Chronic Renal Insufficiency Cohort study; JHS, Jackson Heart Study; MDRD, Modification of Diet in Renal Disease study; PREVEND, prevention of renal and vascular end stage disease study.
All values in table expressed as mean (SD), n (%) or minimum, maximum.
a
To convert serum creatinine from mg/dl to umol/l multiply by 88.4.
b
To convert urine creatinine from mg/d to mmol/d divide by 113.12.
C
n = 9143 in discovery cohort and 4571 in validation cohort with serum creatinine measurements.